Merck & Company, Inc. · NYSE:MRK
Merck & — Shareholder Meeting (May 2026)
32 slides from Merck &'s shareholder meeting presentation, May 26, 2026
Slide 1: Annual Meeting of Shareholders
Annual Meeting of Shareholders Merck & Co., Inc., Rahway, N.J., USA May 26, 2026 1
Slide 2: Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA
Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These state
Slide 3: Annual Meeting of Shareholders - Robert M. Davis
Annual Meeting of Shareholders Robert M. Davis Chairman, Chief Executive Officer and President 3
Slide 4: Nominees for Director
Nominees for Director Robert M. Douglas M. Mary Ellen Coe Pamela J. Craig Thomas H. Surendralal L. Risa J. Lavizzo- Davis Baker, Jr. Glocer Karsanbhai Mourey, M.D. Stephen L. Paul B. Patricia F. Christine E. Inge G. Thulin Kathy J. Warden Mayo, Ph.D. Rothman, M.D. Russo Seidman, M.D. 4
Slide 5: Executive Team
Executive Team Robert M. Davis Richard R. DeLuca, Jr. Brian Foard Chirfi Guindo Betty Larson Dean Y. Li, M.D., Ph.D. Caroline Litchfield Dave Maraldo Jannie Oosthuizen Dave Williams Jennifer Zachary 5
Slide 6: 6
6
Slide 7: Our Purpose
Our Purpose For 135 years, our Company has been guided by one clear and compelling purpose: putting patients first by using the power of leading-edge science to save and improve lives. 7
Slide 8: Full-year 2025 highlights
Full-year 2025 highlights Financial highlights* $ in billions, except Full Year Ex-Exchange % EPS amounts 2025 vs. Prior Sales $65.0 +2% GAAP net income** $18.3 +9% Full-year worldwide sales GAAP EPS*** $7.28 +10% $65.0B Non-GAAP net +2% ex-exchange $22.5 +18% income** Non-GAAP EPS*** $8.98 +19% * A
Slide 9: Transforming our portfolio with next wave of innovation
Transforming our portfolio with next wave of innovation >$70B +$20B opportunity since last year ~$35B Consensus 2028 Mid 2030s revenue total KEYTRUDA opportunity from sales1,2 potential new growth drivers3 1. Total KEYTRUDA sales include KEYTRUDA and KEYTRUDA QLEX 2. Source: Evaluate Pharma consensu
Slide 10: Transforming our portfolio with next wave of innovation
Transforming our portfolio with next wave of innovation >$70B ifinatamab MK-1406 +$20B deruxtecan5 opportunity since last year islatravir based sacituzumab QW regimens4 tirumotecan6 ~$35B enlicitide tulisokibart decanoate MK-3000 Consensus 2028 Mid 2030s revenue total KEYTRUDA opportunity from sales
Slide 11: Strong progress across pipeline and portfolio
Strong progress across pipeline and portfolio Oncology Cardiometabolic and Vaccines and infectious Animal Health respiratory diseases diseases 11
Slide 12: More than $65 billion in strategic business development
Business development to augment strong pipeline More than $65 billion in strategic business development* 12 *Since 2021. Business development figure includes upfront and milestone payments related to acquisitions, strategic collaborations and licensing agreements.
Slide 13: Committed to operating responsibly and delivering long-term, sustainable value
Committed to operating responsibly and delivering long-term, sustainable value 400M+ people reached $80B+ invested in U.S. R&D, $70B+ committed to U.S. with our medicines and vaccines in 2025 $12B+ in U.S. manufacturing manufacturing & R&D Between 2018 and 2024 over the next several years 13
Slide 14: 14
14
Slide 15: Annual Meeting of Shareholders - Dean Y. Li
Annual Meeting of Shareholders Dean Y. Li, M.D., Ph.D. Executive Vice President and President, Research Laboratories 15
Slide 16: Progress across oncology development program
Progress across oncology development program I-DXd1 B7-H3-directed ADC • 3 Phase 3 studies in multiple cancers • Under priority review by U.S. FDA for treatment of certain patients with extensive-stage small cell lung cancer, based on Phase 2 IDeate-Lung01 study • Primary completion dates for Phase
Slide 17: Clinical and regulatory advancements across cardiometabolic and respiratory pipeline
Clinical and regulatory advancements across cardiometabolic and respiratory pipeline Enlicitide decanoate Phase 3 results support ambition to bring first approved oral PCSK9i to broad population globally Phase 3 study in adults with or at-risk for atherosclerotic cardiovascular disease – Findings pr
Slide 18: Advancing pipeline across infectious diseases, immunology and ophthalmology
Advancing pipeline across infectious diseases, immunology and ophthalmology HIV Infectious diseases IDVYNSO (doravirine/islatravir) MK-1406 • April FDA approval for first non-integrase strand • Potential first-in-class long-acting influenza transfer inhibitor, tenofovir-free, complete two antiviral
Slide 19: 19
19
Slide 20: Nominees for Director
Nominees for Director Robert M. Douglas M. Mary Ellen Coe Pamela J. Craig Thomas H. Surendralal L. Risa J. Lavizzo- Davis Baker, Jr. Glocer Karsanbhai Mourey, M.D. Stephen L. Paul B. Patricia F. Christine E. Inge G. Thulin Kathy J. Warden Mayo, Ph.D. Rothman, M.D. Russo Seidman, M.D. 20
Slide 21: 21
21
Slide 22: Proposal 4 – Shareholder Proposal
Proposal 4 – Shareholder Proposal 22
Slide 23: 23
23
Slide 24: Proposal 5 – Shareholder Proposal
Proposal 5 – Shareholder Proposal 24
Slide 25: 25
25
Slide 26: Proposal 6 – Shareholder Proposal
Proposal 6 – Shareholder Proposal 26
Slide 27: 27
27
Slide 28: Question & Answer
rs & Question & Answer
Slide 29: 29
29
Slide 30: Thank you
Thank you Copyright © 2026 Merck & Co., Inc., Rahway, N.J., USA and its affiliates. All rights reserved. 30
Slide 31: Appendix
rs & Appendix
Slide 32: Glossary
Glossary AHA/ACC = American Heart Association/American College of Cardiology PCSK9 = Proprotein convertase subtilisin/kexin type 9 AMD = Age-related macular degeneration RSV = Respiratory syncytial virus ApoB = Apolipoprotein B sac-TMT = Sacituzumab tirumotecan B7-H3 = B7 homolog 3 SSc-ILD = Systemi